What Is Barrett's Esophagus?
Barrett's esophagus happens when stomach acid repeatedly damages the lower part of the food pipe. Over time, the normal cells there change into a different type — called intestinal metaplasia (IM) — that doesn't belong in the esophagus. In some people, those cells go a step further and become dysplasia (abnormal cell growth), which can eventually lead to esophageal cancer.
About 3 to 6 million Americans have Barrett's esophagus. Most never develop cancer, but those who do face a serious diagnosis. Doctors have been searching for reliable ways to eradicate those abnormal cells early, before things progress.
From Heat to Cold: A New Approach
For years, the go-to treatment was radiofrequency ablation (RFA) — using heat delivered through a special scope to burn away the abnormal tissue. It works well, but it's not perfect. Some patients don't respond, and the equipment requires careful technique.
But here's the twist: a newer approach uses extreme cold instead of heat. This technique — called focal cryoballoon ablation, or FCBA — freezes the lining of the esophagus with a balloon-tipped device cooled by nitrous oxide gas. The frozen cells die and are replaced by healthy tissue. Think of it like pressing a tiny ice pack directly against a patch of trouble cells.
The cryoballoon is inserted through a standard endoscope (a flexible camera tube passed through the mouth). When the balloon contacts the esophagus wall and inflates, it delivers a precise burst of freezing cold. Abnormal cells — more fragile than healthy ones — cannot survive the temperature drop. Healthy tissue around them, however, tends to recover.
The procedure is done in multiple sessions, usually spaced three months apart, until all the abnormal tissue is gone.
Who Was in This Study?
Researchers across multiple European medical centers enrolled 107 patients with Barrett's esophagus. Participants had shorter affected segments — no longer than about two inches — with early signs of abnormal cell growth or very early cancer. About two-thirds had visible lesions removed first using a separate endoscopic technique. Then they began the FCBA treatment series. The study tracked outcomes for an average of 18 months.
The results were striking. In 94% of patients, all visible signs of Barrett's tissue were completely gone. Doctors confirmed that 91% had no remaining trace of the abnormal cell type even on biopsy. In patients who completed the full protocol as planned, complete eradication reached 100% for visible disease and 96% for microscopic changes.
At 18 months of follow-up, 96% of those who achieved clearance remained free of any visible Barrett's tissue. That kind of durability is what makes this procedure stand out.
This doesn't mean FCBA is right for everyone with Barrett's esophagus — patient selection matters a great deal.
The One Concern Worth Noting
That's not the full story. About 13% of patients developed a stricture — a narrowing of the esophagus — after treatment. This can make swallowing difficult. In most cases, strictures can be managed with a stretching procedure, but it's a complication that deserves attention. Researchers say more work is needed to understand who is most at risk and how to prevent it.
Where Does This Fit?
This study adds to a growing body of evidence that cryoablation is a real contender in the Barrett's treatment toolbox. Experts in the field note that having multiple effective options matters — because not every patient responds the same way to every approach. The multicenter design of this study, spread across several European hospitals, adds credibility to the findings and suggests the procedure can be performed consistently in different settings.
If you have Barrett's esophagus and have been told you have dysplasia (abnormal cells), it's worth asking your gastroenterologist about ablation options, including cryoballoon therapy. This treatment is available at some specialized endoscopy centers. Your eligibility will depend on the length of your Barrett's segment and the severity of cell changes.
This was a relatively small study of 107 patients, conducted at specialized centers in Europe — which means results may differ at community hospitals with less experience. The follow-up period was 18 months, which is helpful but not long enough to confirm lifelong protection against cancer. Larger and longer studies are still needed.
Researchers plan to investigate strategies to reduce the risk of esophageal stricture, which remains the main downside of FCBA. Longer follow-up studies will also be needed to confirm how well the treatment holds up over years — and whether it truly prevents cancer in the long run. If those results continue to look promising, FCBA may become a standard option at more centers worldwide.
